logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
Therapeutic Advances in Drug Safety cover

Therapeutic Advances in Drug Safety

IF3.4
Papers462
Citations1675
Journal Papers 462
Publication Date
delete
Multisystem adverse drug events of low-dose tirzepatide in a normal - Weight individual: A case report and literature review
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-10-03
delete0
PREAI
deleteMeixia Li; Congkai Zhou; Jinggang Zhou
deleteShare
deleteSave
Comparative pharmacovigilance of glycaemic adverse-event reporting for alpelisib and capivasertib: A disproportionality analysis of the FDA adverse event monitoring system
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-09-30
delete0
PREAI
deleteYongjian Liu; Hao Zhong; Xingjun Huang; Yige Yu; Shuzhen Liu; Yingyu Yu
deleteShare
deleteSave
Risk of Clostridioides difficile infection with potassium-competitive acid blockers: A systematic review with restricted quantitative synthesis
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-09-28
delete0
PREAI
deleteAh Young Lee; Kwanjoo Lee; Sun Jae Moon; Seung-Hun You; Jun-young Seo; Wonsuk Shin
deleteShare
deleteSave
Comment on “Machine learning studies of drug-induced nephrotoxicity: A scoping review”. The missing role of causality
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-09-24
delete0
PREAI
deleteIzak A. R. Yasrebi-de Kom; Joanna E. Klopotowska
deleteShare
deleteSave
Safety-guided selection of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: toxicity profiles, dose modification, and clinical risk–benefit considerations
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-09-16
delete0
PREAI
deleteNidhi Shrivastava; Santosh Laxman Gaonkar; Fayaz Shaik Mahammad
deleteShare
deleteSave
Transient monocular vertical hemifield loss as a rare acute oxaliplatin-induced ophthalmological side effect: a case report and review of the literature
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-09-01
delete0
PREAI
deleteLucie Regaldo-Saint Blancard; Simon Pernot; Marianne Fonck; Lola Jade Palmieri
deleteShare
deleteSave
Evaluation of digoxin dosing and therapeutic drug monitoring in adult patients receiving continuous venovenous hemodiafiltration
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-09-01
delete0
PREAI
deleteMadison P. Nordin; Jenna F. Cox; Bryan L. Love; Breanne Mefford
deleteShare
deleteSave
An assessment of medication errors and associated factors to strengthen patient safety practices in a tertiary hospital in Cameroon
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-08-21
delete0
PREAI
deleteAlberic Ndonku Signang; Mbohjim Othniel Mobit; Taneh Yvonne Shee; Jaques Van Heerden
deleteShare
deleteSave
Factors associated with medication administration errors in hospitalized pediatric patients: A scoping review
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-08-21
delete0
PREAI
deleteClaudia Lorena Motta Robayo; Jonathan Martínez Pinto; Bryan Tabango Goyes; Laura Varela Chagüendo; Eduardo Duque Grisales; Ricardo Ballesteros-Ramírez
deleteShare
deleteSave
Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-08-18
delete0
PREAI
deleteWei-Yang Xue; Xi Li; Wen-Ting Li; Bao-Zhi Qin; Cong-Zhi Wang; Tao Liu; Min Wang
deleteShare
deleteSave
Development and validation of a MedDRA-based signal detection construct for drug-induced neurobehavioral impairment
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-08-03
delete0
PREAI
deleteChristopher D. Breder
deleteShare
deleteSave
Disproportionality analysis of off-label intravitreal bevacizumab in the FDA Adverse Event Reporting System database
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-07-28
delete0
PREAI
deleteHomero Contreras-Salinas; Janet Cristina Vázquez-Beltrán; Gisela García-Sánchez; Sebastian Quirarte-Justo; Sarahí del Carmen Gómez-Macías; Lourdes Yolotzin Rodríguez-Herrera
deleteShare
deleteSave
Development and prospective validation of a machine learning model for risk stratification of drug-induced liver injury using real-world clinical data
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-07-25
delete0
PREAI
deleteNgan Thi Tran; Tung My Pham; Mai Thi Quynh Ngo; Anh Van Tran; Thu Thi Kim Ninh; Long Duc Nguyen; Dung Van Hoang; Phuong Thi Thu Nguyen
deleteShare
deleteSave
Sex-specific risk factors for genital infections associated with SGLT2 inhibitors in type 2 diabetes: a retrospective cohort study and disproportionality analysis using JADER
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-07-20
delete0
PREAI
deleteAyami Kajiwara-Morita; Sawa Kugimoto; Kentaro Oniki; Akira Yoshida; Noboru Kurinami; Tomoko Suzuki; Fumio Miyamoto; Kunio Hieshima; Seigo Sugiyama; Keizo Kajiwara; Katsunori Jinnouchi; Hideaki Jinnouchi; Junji Saruwatari
deleteShare
deleteSave
Prolonged neonatal phosphate retention and transient hypercalcemia following antenatal Burosumab exposure: a pharmacovigilance alert
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-07-12
delete0
PREAI
deleteGuido Filler; Funmbi Babalola; Andrea Cowan; Tayyab Khan; Leanne Ward
deleteShare
deleteSave
Team approach to polypharmacy evaluation and reduction for general practice patients with dementia: the Australian TAPERDem study
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-07-10
delete0
PREAI
deleteChristopher Etherton-Beer; Amy Theresa Page; Hui Wen Quek; Lynne Parkinson; Vasi Naganathan; Gillian Caughey; Julie Redfern; Rhonda Clifford; Sarah Hilmer; Dee Mangin
deleteShare
deleteSave
Sequential analysis for post-marketing drug safety surveillance using routinely collected electronic healthcare data: a scoping review
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-07-07
delete0
PREAI
deleteYixin Sun; Qian Ding; Hongting Nie; Peng Guo
deleteShare
deleteSave
Drug interactions in rheumatoid arthritis: a disparity between electronic database prediction and real-world co-prescription with different large language models
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-06-24
delete0
PREAI
deleteTonson Lalitkanjanakul; Dhanesh Pitidhammabhorn; Natnicha Jakramonpreeya; Werapat Suechanyapong; Supawit Tangpanithandee; Phisit Khemawoot
deleteShare
deleteSave
Muscle relaxant use and the associated risk of Sjögren’s syndrome and dry eye disease (including keratoconjunctivitis sicca) in patients with ankylosing spondylitis: a population-based cohort study
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-06-23
delete0
PREAI
deleteWeijie Wang; Jingyang Huang; Shujun Xia; Lin Cai; James Cheng-Chung Wei
deleteShare
deleteSave
Safety of belimumab during pregnancy: associations with maternal and fetal or newborn adverse outcomes based on FAERS data
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-06-18
delete0
PREAI
deleteYujie Lin; Jing Yao
deleteShare
deleteSave